Vuzix Smart Glasses Power Enterprise Deployments in Warehouse and Logistics for Major Multinational
ROCHESTER, N.Y., May 16, 2025 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of AI-powered smart glasses, waveguides, and Augmented Reality (AR) technologies, today acknowledged a public post made by Amazon on LinkedIn, which highlighted the use of Vuzix smart glasses to enhance warehouse operations.
According to the post, the smart glasses are supporting Reliability and Maintenance Engineering (RME) teams by enabling "see what I see" functionality—allowing central experts to virtually diagnose and resolve complex equipment issues in real time. This approach is improving safety, accelerating repairs, and enhancing productivity within large-scale logistics facilities.
Vuzix smart glasses have been purchased by the customer and are currently deployed to support maintenance operations and remote collaboration.
"This is another clear example of how Vuzix smart glasses are delivering real-world value to some of the world's most sophisticated enterprises," said Paul Travers, President and CEO of Vuzix. "We're proud to support customers embracing wearable technologies to drive safety, efficiency, and digital transformation at scale."
About Vuzix Corporation
Vuzix is a leading designer, manufacturer and marketer of AI-powered Smart Glasses, Waveguides and Augmented Reality (AR) technologies, components and products for the enterprise, medical, defense and consumer markets. The Company's products include head-mounted smart personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality, as well OEM waveguide optical components and display engines. Vuzix holds more than 425 patents and patents pending and numerous IP licenses in the fields of optics, head-mounted displays, and the augmented reality wearables field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2024 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in: Rochester, NY; and Kyoto and Okayama, Japan. For more information, visit the Vuzix website, X and Facebook pages.
Forward-Looking Statements Disclaimer
Certain statements contained in this news release are "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward-looking statements contained in this release relate to Vuzix Smart Glasses, our business relationship and future business opportunities with Amazon, and among other things the Company's leadership in the Smart Glasses and AR display industry. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
Vuzix Media and Investor Relations Contact:
Ed McGregor, Director of Investor Relations,Vuzix Corporationed_mcgregor@vuzix.com Tel: (585) 359-5985
Vuzix Corporation, 25 Hendrix Road, West Henrietta, NY 14586 USA,Investor Information – IR@vuzix.com www.vuzix.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vuzix-smart-glasses-power-enterprise-deployments-in-warehouse-and-logistics-for-major-multinational-302457843.html
SOURCE Vuzix Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Novoxel Inc. and GPOphtho Finalize Strategic Agreement to Deliver Breakthrough Dry Eye Treatments and Aesthetic Procedures to Eyecare Physicians Nationwide
KNOXVILLE, Tenn., May 31, 2025 /PRNewswire/ -- Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel's innovative Tixel® device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to eyecare physicians nationwide. Expanding Access to Advanced Dry Eye and Aesthetic Solutions The agreement grants GPOphtho's network of ophthalmologists and optometrists discounted pricing and value-added packages for Novoxel's Tixel devices. Tixel i® is specifically designed to treat Meibomian Gland Dysfunction (MGD), offering a fast and targeted solution for both upper and lower eyelids. A recent clinical trial (Sanni, et al, 2025) concluded that Tixel i is a safe, non-pharmacologic, first-line treatment for MGD. "What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. The FDA-cleared family of products provide year-round treatments for all skin types and age groups. They offer non-invasive rejuvenation without needles, bleeding, or pain, minimal downtime, no expensive consumables, and are radiation-free. Empowering Eyecare Physicians with New Revenue Streams "Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. This agreement will enable eyecare professionals to easily integrate both functional and cosmetic procedures, creating new revenue streams and enhancing patient satisfaction. Both Novoxel and GPOphtho are committed to bringing innovative, cutting-edge technology to more patients and practices across the US. For product demos or pricing information, visit Existing GPOphtho members can inquire about adding Tixel through their GPOphtho contact. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation. Novoxel has been granted numerous patents around the world. The company's Tixel family of products use proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results even though treatments are non-invasive. There is minimal downtime, no expensive single-use cartridges, no bleeding, and minimal/no pain. Because the affordable treatments are radiation-free, safety eyewear is not required for clinicians. Visit for more information. ABOUT GPOPHTHOGPOphtho's mission is to save our members time and money for all of their business needs by becoming the most comprehensive ophthalmic group purchasing organization. By leveraging collective buying power, GPOphtho is able to negotiate discounted rates and value-added packages for a diverse range of products and services, allowing physicians and their staff to focus on providing the best care for their patients. Plus, members can take advantage of all GPOphtho's negotiated contracts without paying administrative fees. For more information, visit Interested eyecare physicians can join GPOphtho at no cost. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Why Summit Therapeutics Plunged Today
Summit Therapeutics released more data from another HARMONi phase 3 trial. Results were "mixed," which perhaps led to some disappointment in this stock, which had rocketed higher over the past year. Still, all hope is not lost, analysts say. 10 stocks we like better than Summit Therapeutics › Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning. Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed prior standards of care in phase 3 trials performed in China by Summit's partner Akeso (OTC: AKES.F). While today's results weren't all bad by any means, apparently investors had hoped for more conclusive information about survival rates. With such high expectations, it appears investors are taking profits or de-risking in a big way. Today's release showed results of the fourth phase 3 trial known as "HARMONi," the first to include a significant Western patient population (about a third of participants). Last year's positive results largely came from a China-only study. On the positive side, today's data did show that ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 48%. In addition, the company noted no significant differences between the Asian and Western patient populations. However, the trial didn't show a "statistically significant" benefit in overall survival. Summit has been hoping to apply for FDA approval for ivonescimab in the U.S., but the FDA has told the company it will need to show that statistically significant survival benefit in order to get it. Investors may be getting nervous about that eventual approval. However, analysts don't believe investors should panic. Jefferies biotech analyst Kelly Shi noted the survival endpoint still has a chance of being reached as the data matures further and Western trial patients continue to show survival benefits. So basically, it doesn't appear as though the trial has lasted long enough to reach the statistically significant survival threshold, which doesn't mean that it won't get there. Another analyst was also bullish on the data, despite today's drop. Cantor Fitzgerald biotech analyst Eric Schmidt said, "We think it is fairly clear that this is a drug! ... In each of these four trials, the data posted by ivonescimab appear differentiated from and superior to PD-1 therapy." Therefore, investors may want to take a look at Summit on this drop. While today's data didn't meet the threshold many investors had been hoping for, there is still a chance that it will with more time. Given the success ivonescimab has demonstrated over the past year, it seems likely, though not certain, the drug will eventually be approved. Of course, it's a bit difficult to value a stock like Summit, which has a promising drug candidate but no real current revenues and a market cap that, even down 30% today, is still over $13.5 billion. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group and Summit Therapeutics. The Motley Fool has a disclosure policy. Why Summit Therapeutics Plunged Today was originally published by The Motley Fool
Yahoo
32 minutes ago
- Yahoo
Casio to Release New MT-G Featuring an Original Frame Co-Created by Humans and AI
Newly Developed Structure Fusing Different Materials TOKYO, May 27, 2025 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the latest addition to the G-SHOCK brand of shock-resistant watches: the MTG-B4000. This new timepiece features a distinctive frame developed in a process of collaboration between human designers and AI technology. The MTG-B4000 joins the MT-G line of timepieces, all of which utilize a unique construction that makes the most of the properties of both metal and resin. The new MTG-B4000 is a shock-resistant watch featuring a distinctive frame that was developed in a process of collaboration between human designers and generative AI and uses a combination of different materials. For the first time in a Casio consumer timepiece, generative AI technology was integrated into the development process. In pursuit of innovative craftsmanship, designers employed this advanced technology as a creative tool to explore new design possibilities and conquer the challenge of realizing a complex, unconventional structure which would have been difficult to achieve using traditional methods. Starting with design proposals from human designers, AI conducted load simulations using decades of accumulated data on shock-resistant construction for G-SHOCK. It then proposed optimal structural configurations by evaluating factors such as structural strength, material characteristics, and machinability. These AI-generated designs were refined through repeated testing and adjustments by skilled human hands, resulting in a frame that delivers the G-SHOCK signature ruggedness with a distinctive, unconventional aesthetic only achievable through AI collaboration. A new approach was also introduced by integrating the band connection parts into the frame. This allows the frame to directly absorb loads applied to the band, reducing impact on the center case and further enhancing shock resistance. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. Any use of such marks and logos by Casio Computer Co., Ltd. is under license. View original content to download multimedia: SOURCE CASIO COMPUTER CO., LTD Sign in to access your portfolio
